This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Is Cancer the Next Breakthrough for Moderna After COVID-19?
by Sundeep Ganoria
MRNA's cancer therapy scores a first phase III win, fueling hopes its mRNA platform can drive growth beyond COVID-19 vaccines.
MRNANegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Biotech ETF (CANC) Hits New 52-Week High
by Sanghamitra Saha
CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.
CANCNegative Net Change
biotechs
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
by Zacks Equity Research
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
CYTKNegative Net Change BMYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
by Ekta Bagri
Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.
LQDAPositive Net Change JNJNegative Net Change UTHRNegative Net Change
biotechnology biotechs medical pharmaceuticals
From COVID to Cancer: Moderna Scores Melanoma Breakthrough
by Andrew Rocco
By successfully applying individualized mRNA technology to train the immune system against recurring tumor cells, Moderna and Merck have opened an extraordinary new frontier in targeted cancer treatment.
MRKNegative Net Change MRNANegative Net Change
biotechnology biotechs
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
by Ahan Chakraborty
Eli Lilly's GLP-1 portfolio outpaces its rival in Q2, while Foundayo gains momentum and can challenge Wegovy's early oral obesity lead.
LLYNegative Net Change NVONegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment
by Zacks Equity Research
BMRN's $490M Alesta deal adds ALE1, a potential oral HPP therapy, broadening its rare bone disease portfolio and clinical pipeline.
BMRNPositive Net Change AZNNegative Net Change RGENPositive Net Change ANIKNegative Net Change
biotechs medical pharmaceuticals
Earnings, Cancer Vaccine, Long-Term Liquidity: A Busy Pre-Market
by Mark Vickery
Q2 retail earnings continue, Moderna sees positive Phase 3 results, and the Treasury lowers the longer-term bond rate.
MRKNegative Net Change TGTPositive Net Change TJXNegative Net Change LOWNegative Net Change ELNegative Net Change MRNANegative Net Change
biotechnology biotechs cancer earnings finance
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
by Ekta Bagri
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
GILDNegative Net Change GSKNegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
by Zacks Equity Research
AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.
AZNNegative Net Change MRKNegative Net Change HCMPositive Net Change
biotechs medical pharmaceuticals